Category Archives: Cancer Knowledge

Abnormal properties of cancer protein revealed in fly eyes

In a paper featured on the cover of the current issue of the Journal of Biological Chemistry, Michigan State University researchers provide the first detailed examination of a set of mutations similar to those present in the human cancer gene, said Irina Pushel, MSU undergraduate and co-author. “By systematically evaluating mutations of increasing severity, we now have a model to better predict how we think the protein will react with each mutation,” said Pushel, who co-authored the paper with Liang Zhang, lead author and MSU graduate student, and Bill Henry and David Arnosti, MSU molecular biologists. …

Role of hormone in response to ovarian cancer treatment

The work comes out of the molecular therapeutic laboratory directed by Richard G. Moore, MD, of Women & Infants’ Program in Women’s Oncology. Entitled “HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation,” the research was recently published in the international science journal Scientific Reports, a Nature publishing group. The goal of the study was to investigate the role of the hormone HE4 in modulating an ovarian cancer’s response to hormones and hormonal therapies. …

Re-expression of an embryonic signaling pathway in Melanoma utilizes different receptors

During early vertebrate development, Nodal, an embryonic growth factor that governs the growth, pattern and position of tissues, is critical for normal maturation. Nodal plays a significant role in maintaining the pluripotency of embryonic stem cells, meaning the ability of stem cells to differentiate into any of the three germ layers that comprise the body. The recent discovery of Nodal’s re-expression in several aggressive and metastatic cancers has highlighted its critical role in self-renewal and maintenance of the stem cell-like characteristics of tumor cells such as melanoma. However, the signaling pathway receptors utilized by melanoma cells to propagate Nodal’s effect remain(s) mostly anecdotal and unexplored…

New knowledge of genes driving bladder cancer points to targeted treatments — ScienceDaily

Specifically, the study examined a mutation-rich layer of the genome called the exome of 54 bladder tumors from primarily Caucasian patients. The study is the first to show alterations in the gene BAP1 in 15 percent of tumors; the gene is a likely tumor suppressor and so bladder cancers with alterations in this gene may be without an important check on the growth and survival of bladder cancer tissue…

Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning — ScienceDaily

Looking over data gathered from more than 17,000 surveys completed by men diagnosed with prostate cancer, Fox Chase researchers tracked when patients’ urinary and sexual symptoms changed following each type of treatment, and by how much. “The ultimate goal,” says study author Matthew Johnson, MD, Resident Physician in the Department of Radiation Oncology at Fox Chase, “is to develop a predictive tool that lets patients decide which treatment is right for them based on the symptoms they have beforehand, and their tolerance for any change — even temporary — in those symptoms.” After a diagnosis of prostate cancer, men have multiple treatment options, including surgery to remove the prostate and several types of radiation therapy…

Patients who never smoked or who quit smoking have lower risk of developing secondary cancers

The analysis studied the association between patients’ smoking histories and their risks of developing SPLC, which is defined as a new lung cancer unrelated to the initial tumor based on histology and location in the lung. The study analyzed 1,484 patients (372 current smokers, 1,014 former smokers and 98 never smokers) who underwent surgery, with or without adjuvant chemotherapy or radiation therapy, for stage I-IIIA NSCLC at Duke University Medical Center between 1995 and 2008. Baseline covariates and oncologic outcomes including local control (LC), development of distant metastases (DM), overall survival (OS) and rates of SPLC were assessed. …

Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning

Looking over data gathered from more than 17,000 surveys completed by men diagnosed with prostate cancer, Fox Chase researchers tracked when patients’ urinary and sexual symptoms changed following each type of treatment, and by how much. “The ultimate goal,” says study author Matthew Johnson, MD, Resident Physician in the Department of Radiation Oncology at Fox Chase, “is to develop a predictive tool that lets patients decide which treatment is right for them based on the symptoms they have beforehand, and their tolerance for any change — even temporary — in those symptoms.” After a diagnosis of prostate cancer, men have multiple treatment options, including surgery to remove the prostate and several types of radiation therapy. They can receive external beam radiation directed towards their prostate, known as intensity modulated radiation therapy (IMRT), or undergo a procedure that implants radioactive seeds in their prostate called low dose rate brachytherapy (LDR). …